Structural basis of inhibition of the human serine hydroxymethyltransferase SHMT2 by antifolate drugs

Research output: Contribution to journalArticle

Abstract

Serine hydroxymethyltransferase (SHMT) is the major source of 1-carbon units required for nucleotide synthesis. Humans have cytosolic (SHMT1) and mitochondrial (SHMT2) isoforms, which are upregulated in numerous cancers, making the enzyme an attractive drug target. Here, we show that the antifolates lometrexol and pemetrexed are inhibitors of SHMT2 and solve the first SHMT2-antifolate structures. The antifolates display large differences in their hydrogen bond networks despite their similarity. Lometrexol was found to be the best hSHMT1/2 inhibitor from a panel antifolates. Comparison of apo hSHMT1 with antifolate bound hSHMT2 indicates a highly conserved active site architecture. This structural information offers insights as to how these compounds could be improved to produce more potent and specific inhibitors of this emerging anti-cancer drug target.

Details

Authors
Organisations
External organisations
  • Stockholm University
  • Karolinska Institutet
  • University of Sheffield
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cell and Molecular Biology
Original languageEnglish
JournalFEBS Letters
Publication statusE-pub ahead of print - 2019 May 25
Publication categoryResearch
Peer-reviewedYes

Bibliographic note

© 2019 Federation of European Biochemical Societies.